Analyst Charles Rhyee from TD Cowen maintained a Hold rating on IQVIA Holdings and decreased the price target to $174.00 from $245.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Rhyee has given his Hold rating due to a combination of factors tied to both valuation and emerging AI-related risks. He acknowledges that IQVIA’s 2026 earnings outlook is solid and within the company’s guidance range, but he also sees the need to temper expectations as revenue and EBITDA projections suggest more measured growth than previously assumed.
At the same time, Rhyee believes AI will eventually disrupt the contract research model, even if the timing and magnitude remain unclear. While regulatory hurdles and IQVIA’s proprietary data assets may cushion the impact and even create new opportunities, he expects AI concerns to weigh on the stock’s valuation multiples for some time, leading him to lower his price target and maintain a neutral, Hold stance.
According to TipRanks, Rhyee is a 4-star analyst with an average return of 2.7% and a 50.20% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Cardinal Health, Cigna, and IQVIA Holdings.
In another report released on February 15, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $174.00 price target.